On July 31, 2025, SciSparc Ltd. announced an amendment to a letter of intent with Miza III Ventures, extending the deadline for a definitive agreement to October 15, 2025. Additionally, they informed about a collaboration resulting in a patent application for a therapy targeting weight loss and fatty liver disease.